IATP Congratulates Yoplait on Eliminating rBGH

General Mills' Yoplait brand announced today that by August 2009
it would stop using milk from cows injected with the synthetic hormone, recombinant Bovine Growth Hormone (rBGH). The Institute for Agriculture and Trade
Policy (IATP) congratulates Yoplait on its decision.

"Yoplait joins a growing number of companies that have listened to consumers and
rejected dairy from cows injected with rBGH," said David Wallinga, M.D., Director
of IATP's Food and Health Program. "The marketplace is following the public health
community, which has long been cautioning about the unnecessary use of routine
hormones and antibiotics in raising food animals."

Fortunately for Minnesotans, Yoplait is just the latest addition to a long list of companies offering milk, cheese and other products from cows not injected with rBGH.
To help consumers find such producers, IATP has published the new consumer
Smart Guide to Minnesota Dairy Without rBGH, available at: www.iatp.org.

When rBGH arrived on the market as Posilac in 1994, it was one of the first genetically engineered agriculture products. Posilac was marketed as a way for dairy
farmers to improve income by slightly increasing milk production. But 15 years
later, dairy farmers are experiencing the largest price drop in 50 years. And a
side effect of rBGH (listed on the label) is the propensity for the hormone to make
cows sick with udder infections, leading to suffering and forcing farmers to increase their antibiotic use.

"Avoiding antibiotic use wherever possible is an important public health goal, because there is now a consensus among scientists that antibiotic use in farm animals increases antibiotic resistance, often transmitted back to humans," said Dr.
Wallinga.

Use of rBGH also raises levels of Insulin-like Growth Factor-1 (IGF-1) in cows and
cow's milk. Higher IGF-1 levels in human blood are associated with higher rates of
colon, breast and prostate cancer. What scientists still lack are sufficient data to
assure that drinking milk with higher IGF-1 levels, from rBGH-treated cows, won't
translate into higher IGF-1 levels in the blood of the consumer.

Consumers have become increasingly concerned about these rBGH risks. Almost
60 percent of U.S. consumers state that they would pay a premium for dairy
products coming from cows not treated with the hormone. And because of various
rBGH risks, the hormone has not been approved in Canada, Australia, New Zea-
land, Japan, or the 27 countries of the European Union.